Female sex, antidepressant use, and type of health insurance significantly influence semaglutide initiation. (HealthDay News) — Sociodemographic, health care, and clinical factors are associated with ...

Significant associations for semaglutide initiation included being female, using certain medication classes including antidepressants, and being covered by a point-of-service plan. (HealthDay News ...

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...

Good response to obesity treatment or achieving ... to compare the prevalence of cardiovascular outcomes, like type 2 diabetes, hypertension and dyslipidemia in adulthood. The researchers followed ...

The FDA has approved a new indication for semaglutide to lower the risk for worsening kidney disease, kidney failure and cardiovascular death among adults with type 2 diabetes and chronic kidney ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Additionally, semaglutide has been linked to improved cardiovascular outcomes in individuals with obesity but without diabetes, indicating its potential to address multiple health concerns ...

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, ...

Recently, an international commission proposed a revised definition of obesity that focuses ... published January 14 in the journal The Lancet Diabetes & Endocrinology, could shift the paradigm ...